A value-based formulary was implemented that used cost-effectiveness analysis to inform medication co-payments. Diabetes cohort expenditures decreased by $9 per member per month.
Authors from The Brookings Institution update their recommendations by focusing on 3 concrete objectives to slow spending and improve quality of care within the next 5 years.
Many patients with cancer desire cost discussions with doctors, but those discussions are rare. Nevertheless, cost discussions may lower patient costs-usually without altering treatment.
Through analysis of multistate Medicaid data, this study identifies differences in 2 commonly used measures of emergency department (ED) utilization, ED visit count and ED reliance.
This study evaluated the impact of a patient safety intervention and national guideline to reduce unnecessary red blood cell transfusions in a large, urban academic medical center.
This study demonstrates that patients with diabetes taking thiazolidinediones have higher proportions of distal upper and lower limb fractures than those not taking the drug.
Drug therapy management implementation in 2 health plans resulted in significant cost savings and modest to significant reductions in emergency department visits and inpatient admissions among patients with diabetes.
Implementing a claims-based algorithm and disease management program may be an effective strategy to reduce relapse and cost among patients with schizophrenia.
Payers like key traits of pragmatic clinical trials, but are wary of pharmaceutical companies and plan to carefully scrutinize this new, appealing type of evidence.
This article outlines strategies insurers can use to mitigate their risks related to prescription opioid abuse by members, while addressing this serious public health problem.
An interactive voice response system is as effective as nurse phone calls for ensuring that patients attend appointments and are adequately prepared for endoscopy examinations.
Healthcare organizations and researchers should challenge themselves to provide increasingly timely data on cancer care disparities, until delays can be remedied as they happen.
With a “new normal” level of care going forward post coronavirus disease 2019 (COVID-19), the key will be to invest in high-value services while deterring a resurgence of low-value care.
This special issue presents important new peer-reviewed research, covering issues ranging from access and the out-of-pocket costs of a treatment course, to the real-world consequences-both economic and clinical-of failing to treat.
Late hepatitis C virus infection diagnosis points to a need for earlier screening and treatment before the onset of severe liver disease leading to high cost and diminished outcomes.
The authors developed and validated an accurate, well-calibrated, easy-to-implement COVID-19 hospitalized patient deterioration index to identify patients at high or low risk of clinical deterioration.
In treatment of depression with adjunctive aripiprazole, early improvement (week 2) was a significant predictor of remission, and lack of improvement was associated with nonremission.
Patient-centered medical home practices provided better preventive care and disease management with less resource utilization than practices not pursuing PCMH status.
Older patients with colorectal cancer were less likely to undergo surgery, radiation, and chemotherapy; rural patients with colon cancer were less likely to undergo chemotherapy.